1. "Gastrointestinal Oncology Service"
Formats
  1. Journal Article (2302)
  2. Meeting Abstract (1841)
  3. Review (139)
  4. Book Section (123)
  5. Editorial (93)
  6. Guidelines (36)
  7. Correspondence (33)
  8. Conference Paper (23)
  9. Miscellaneous (21)
  10. Research Letter (17)
  11. Book Whole (12)
Groups
  1. Gastrointestinal Oncology Service (4640)
  2. Solid Tumor Oncology Division (4640)
  3. Department of Medicine (4638)
  4. Center for Pancreatic Cancer Research (2270)
  5. Surgery (1040)
  6. Survivorship Research (992)

More Groups

People
  1. Leonard Saltz (790)
  2. Eileen O'Reilly (780)
  3. Ghassan Abou-Alfa (568)
  4. Nancy Kemeny (543)
  5. David Kelsen (537)
  6. David Ilson (433)

More People

Years
  1. 2025 (118)
  2. 2024 (307)
  3. 2023 (362)
  4. 2022 (346)
  5. 2021 (345)
  6. 2020 (326)

More Years

Publications
  1. Journal of Clinical Oncology (1276)
  2. Annals of Oncology (320)
  3. Annals of Surgical Oncology (140)
  4. Cancer (127)
  5. Clinical Cancer Research (107)
  6. Cancer Research (94)

More Publications

Publishers
  1. American Society of Clinical Oncology (1355)
  2. Oxford University Press (447)
  3. Elsevier Inc. (404)
  4. Springer (310)
  5. American Association for Cancer Research (279)
  6. Wiley Blackwell (239)

More Publishers

Results (4640)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • ACCENT-based web calculators to predict recurrence and overall survival in stage III colon cancer
    Journal Article

    Renfro, L. A.; Grothey, A.; Xue, Y.; Saltz, L. B.; André, T.; Twelves, C.; Labianca, R.; Allegra, C. J.; Alberts, S. R.; Loprinzi, C. L.; more...
    JNCI: Journal of the National Cancer Institute (2014)

    Fulltext@MSK | Save
  • Hedgehog signaling maintains gastric cancer stem cells and promotes chemotherapy resistance: Results from laboratory and clinical studies
    Meeting Abstract

    Yoon, C.; Park, D. J.; Schmidt, B.; Thomas, N. J.; Lee, H. J.; Kim, T. S.; Janjigian, Y. Y.; Cohen, D. J.; Yoon, S. S.
    Cancer Research (2014)

    Fulltext@MSK | Save
  • IMMU-130, an SN-38 antibody-drug conjugate (ADC) targeting CEACAM5, is therapeutically active in metastatic colorectal cancer (mCRC): Initial clinical results of two phase I studies
    Meeting Abstract

    Segal, N. H.; Dotan, E.; Berlin, J. D.; Starodub, A. N.; Guarino, M. J.; Saltz, L. B.; Maliakal, P. P.; Govindan, S. V.; Wegener, W. A.; Sharkey, R. M.; more...
    Cancer Research (2014)

    Fulltext@MSK | Save
  • Identifying key molecular events at the onset of melanoma using a neural crest stem cell marker
    Meeting Abstract

    Kaufman, C. K.; Mosimann, C.; White, R. M.; Matos, D.; Zon, L. I.
    Cancer Research (2014)

    Fulltext@MSK | Save
  • A phase II study of afatinib (A) in patients (pts) with metastatic human epidermal growth factor receptor (HER2)-positive trastuzumab (T) refractory esophagogastric (EG) cancer
    Meeting Abstract

    Janjigian, Y. Y.; Imtiaz, T.; Ilson, D. H.; Solit, D. B.; Berger, M. F.; Vakiani, E.
    Cancer Research (2014)

    Fulltext@MSK | Save
  • HER2 directed therapy for gastric/esophageal cancers
    Journal Article

    Won, E.; Janjigian, Y.; Ilson, D. H.
    Current Treatment Options in Oncology (2014)

    Fulltext@MSK | Save
  • Management of gastric cancer
    Journal Article

    Ku, G. Y.; Ilson, D. H.
    Current Opinion in Gastroenterology (2014)

    Fulltext@MSK | Save
  • Greater total dose and duration of treatment with bortezomib are associated with higher incidence of chalazion and other ocular side effects
    Meeting Abstract

    Ganesh, K.; Batlevi, C.; Zhang, Z. G.; Hassoun, H.; Lendvai, N.; Landau, H.; Moskowitz, C. H.; Caron, P.; Motzer, R.; Giralt, S. A.; more...
    Blood (2014)

    Fulltext@MSK | Save
  • 30-day-or-sooner readmissions of gastrointestinal medical oncology patients following cancer center inpatient service discharge: Characteristics and preventability
    Journal Article

    Epstein, A. S.; Crosbie, C.; Martin, S. C.; Egan, B.; Goring, T. N.; Koo, D. J.; Kumar, C. B.; Salvit, C.; Capanu, M.; Chou, J.; more...
    Hospital Practice (2014)

    Fulltext@MSK | Save
  • Phase I study of the selective BRAFV600 inhibitor encorafenib (LGX818) combined with cetuximab and with or without the α-specific PI3K inhibitor alpelisib (BYL719) in patients with advanced BRAF mutant colorectal cancer
    Meeting Abstract

    Tabernero, J.; van Geel, R.; Bendell, J. C.; Spreafico, A.; Schuler, M.; Yoshino, T.; Delord, J. P.; Yamada, Y.; Lolkema, M. P.; Fans, J. E.; more...
    European Journal of Cancer (2014)

    Fulltext@MSK | Save